US4680323A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
Assignee: Individual
•
Filing: 1983-12-01
•
Granted: 1987-07-14
•
Expires: 2003-12-01
Abstract
Abstract A novel pharmaceutical composition is disclosed. It comprises a sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising: (a) 5.5-98.5% by weight of hydroxypropyl methylcellulose; (b) 0.25-4.5% by wieght of hydroxypropyl cellulose; (c) 1-90% by weight of a carboxyvinyl polymer.
Inventors
- 👤 Hans Lowey
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 18:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/02; A61K9/0012; A61K9/0053; A61K9/0056; A61K9/006; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/205; A61K9/2054
Claims Analysis
Total Claims: 34
Claim 1
Independent Claim
34 words
A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising: (a) 5.5-98.5% by weight of hydroxypropyl methylcellulose; (b) 0.25-4.5% by weight of hydroxypropyl cellulose; (c) 1-90% by weight of a carboxyvinyl polymer.
Claim 2
Dependent Claim
34 words
A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising: (a) 5.5-98.5% by weight of hydroxypropyl methylcellulose; (b) 0.25-4.5% by weight of hydroxypropyl cellulose; (c) 1-90% by weight of a carboxyvinyl polymer.
Claim 3
Dependent Claim
33 words
A sustained release pharmaceutical carrier as defined in claim 1 wherein the hydroxypropyl cellulose has a viscosity in the range of 1,000 to 1,500 centipoise for a 2% aqueous solution at 25° C.
Claim 4
Dependent Claim
37 words
A sustained release pharmaceutical carrier as defined in claim 1 adapted for facilitating the absorption of large molecules through the buccal pouch of the mouth containing a sweetening agent at least 30 times as sweet as sugar.
Claim 5
Dependent Claim
27 words
A sustained release pharmaceutical carrier according to claim 1, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
Claim 6
Dependent Claim
34 words
A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising: (a) 10-80% by weight of hydroxypropyl methylcellulose; (b) 1.0-3.5% by weight of hydroxypropyl cellulose; (c) 3-75% by weight of a carboxyvinyl polymer.
Claim 7
Dependent Claim
34 words
A sustained release pharmaceutical carrier suitable for admixture with active ingredients comprising: (a) 10-80% by weight of hydroxypropyl methylcellulose; (b) 1.0-3.5% by weight of hydroxypropyl cellulose; (c) 3-75% by weight of a carboxyvinyl polymer.
Claim 8
Dependent Claim
27 words
A sustained release pharmaceutical carrier according to claim 5, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
Claim 9
Dependent Claim
151 words
A sustained release pharmaceutical carrier suitable for admixture with active ingredients and particularly adapted for preparation of compositions suitable for administration of active ingredients through the buccal pouch of the mouth which comprises: (a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20° C.; (b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20° C.; and (c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20° C.; (d) 0.5-40% by weight of hydroxpropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20° C.; (e) 0.25-4.5% by weight of hydroxypropyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution.
Claim 10
Dependent Claim
151 words
A sustained release pharmaceutical carrier suitable for admixture with active ingredients and particularly adapted for preparation of compositions suitable for administration of active ingredients through the buccal pouch of the mouth which comprises: (a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20° C.; (b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20° C.; and (c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20° C.; (d) 0.5-40% by weight of hydroxpropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20° C.; (e) 0.25-4.5% by weight of hydroxypropyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution.
Claim 11
Dependent Claim
33 words
A sustained release pharmaceutical carrier as defined in claim 7 wherein the hydroxypropyl cellulose has a viscosity in the range of 1,000 to 1,500 centipoise for a 2% aqueous solution at 25° C.
Claim 12
Dependent Claim
27 words
A sustained release pharmaceutical carrier according to claim 7, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
Claim 13
Dependent Claim
43 words
A sustained release pharmaceutical composition which comprises a carrier and an active therapeutic agent incorporated within said carrier, said carrier comprising: (a) 5.5-98.5% by weight of hydroxypropyl methylcellulose; (b) 0.25-4.5% by weight of hydroxypropyl cellulose; (c) 1-90% by weight of a carboxyvinyl polymer.
Claim 14
Dependent Claim
43 words
A sustained release pharmaceutical composition which comprises a carrier and an active therapeutic agent incorporated within said carrier, said carrier comprising: (a) 5.5-98.5% by weight of hydroxypropyl methylcellulose; (b) 0.25-4.5% by weight of hydroxypropyl cellulose; (c) 1-90% by weight of a carboxyvinyl polymer.
Claim 15
Dependent Claim
37 words
A sustained release pharmaceutical carrier as defined in claim 10 adapted for facilitating the absorption of large molecules through the buccal pouch of the mouth containing a sweetening agent at least 30 times as sweet as sugar.
Claim 16
Dependent Claim
24 words
A sustained release pharmaceutical composition as defined in claim 11 wherein said therapeutic agent is present in an amount of 0.25 to 700 mg.
Claim 17
Dependent Claim
29 words
A sustained release pharmaceutical composition as defined in claim 11 wherein the hydroxypropyl cellulose has a viscosity of 1,000 to 1,500 for a 2% aqueous solution at 25° C.
Claim 18
Dependent Claim
22 words
A sustained release pharmaceutical carrier as defined in claim 10 which is zero order with respect to its release of active ingredient.
Claim 19
Dependent Claim
19 words
A sustained release pharmaceutical carrier as defined in claim 10 which is adapted for use in a one-a-day tablet.
Claim 20
Dependent Claim
23 words
A sustained release pharmaceutical composition as defined in claim 10 wherein the said therapeutic agent is present in from 0.25 to 700 mg.
Claim 21
Dependent Claim
32 words
A sustained release pharmaceutical composition as defined in claim 10 wherein the carrier contains hydroxypropyl cellulose having a viscosity of 1,000 to 1,500 centipoise for a 2% aqueous solution at 25° C.
Claim 22
Dependent Claim
27 words
A sustained release pharmaceutical composition according to claim 10, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
Claim 23
Dependent Claim
44 words
A sustained release pharmaceutical composition which comprises a carrier and an active therapeutic agent incorporated within said carrier, said carrier comprising: (a) 10-80% by weight of hydroxypropyl methylcellulose; (b) 1.0-3.5% by weight of hydroxypropyl cellulose; and (c) 3-75% by weight of a carboxyvinyl polymer.
Claim 24
Dependent Claim
44 words
A sustained release pharmaceutical composition which comprises a carrier and an active therapeutic agent incorporated within said carrier, said carrier comprising: (a) 10-80% by weight of hydroxypropyl methylcellulose; (b) 1.0-3.5% by weight of hydroxypropyl cellulose; and (c) 3-75% by weight of a carboxyvinyl polymer.
Claim 25
Dependent Claim
27 words
A sustained release pharmaceutical composition according to claim 19, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
Claim 26
Dependent Claim
147 words
A sustained release pharmaceutical composition adapted for administration via the buccal pouch of the mouth which comprises a sustained release carrier and an active therapeutic agent, said carrier comprising: (a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20° C.; (b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20° C.; and (c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20° C.; (d) 0.5-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20° C.; (e) 0.25-4.5% by weight of hydroxypropyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution.
Claim 27
Dependent Claim
147 words
A sustained release pharmaceutical composition adapted for administration via the buccal pouch of the mouth which comprises a sustained release carrier and an active therapeutic agent, said carrier comprising: (a) 2-35% by weight of hydroxypropyl methylcellulose having a viscosity of about 50 centipoise for a 2% aqueous solution at 20° C.; (b) 3-85% by weight of hydroxypropyl methylcellulose having a viscosity of about 4,000 centipoise for a 2% aqueous solution at 20° C.; and (c) 2-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 15,000 centipoise for a 2% aqueous solution at 20° C.; (d) 0.5-40% by weight of hydroxypropyl methylcellulose having a viscosity of about 100,000 centipoise for a 2% aqueous solution at 20° C.; (e) 0.25-4.5% by weight of hydroxypropyl cellulose; and (f) 1-90% of a carboxyvinyl polymer having a viscosity of 30,000 to 40,000 centipoise for a 3.0% by weight neutralized solution.
Claim 28
Dependent Claim
27 words
A sustained release pharmaceutical composition according to claim 21, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
Claim 29
Independent Claim
166 words
A method for producing a sustained zero-order time release of an active pharmaceutical agent in the gastro-intestinal tract comprising: forming an ingestible tablet containing a carrier of hydroxypropyl methylcellulose, hydroxypropyl cellulose and a carboxy vinyl polymer, together with an effective amount of a pharmaceutically active agent; ingesting the tablet; and allowing the tablet to transit the gastro-intestinal tract and to slowly dissolve by the action of gastro-intestinal fluids thereupon, whereby the weakly acidic carboxy vinyl polymer reacts to form salts under the alkaline conditions in the small intestine of the gatro-intestinal tract to thereby produce a coating of the active pharmaceutical agent on the small intestine of the gastro-intestinal tract, which coating remains in place and from which the pharmaceutically active agent is slowly absorbed through the mucosa of the small intestine into the blood stream over a sustained period of from twelve to twenty-four hours, which is in excess of the time taken by an undissolved remnant of the tablet to transit the gastro-intestinal tract.
Claim 30
Independent Claim
166 words
A method for producing a sustained zero-order time release of an active pharmaceutical agent in the gastro-intestinal tract comprising: forming an ingestible tablet containing a carrier of hydroxypropyl methylcellulose, hydroxypropyl cellulose and a carboxy vinyl polymer, together with an effective amount of a pharmaceutically active agent; ingesting the tablet; and allowing the tablet to transit the gastro-intestinal tract and to slowly dissolve by the action of gastro-intestinal fluids thereupon, whereby the weakly acidic carboxy vinyl polymer reacts to form salts under the alkaline conditions in the small intestine of the gatro-intestinal tract to thereby produce a coating of the active pharmaceutical agent on the small intestine of the gastro-intestinal tract, which coating remains in place and from which the pharmaceutically active agent is slowly absorbed through the mucosa of the small intestine into the blood stream over a sustained period of from twelve to twenty-four hours, which is in excess of the time taken by an undissolved remnant of the tablet to transit the gastro-intestinal tract.
Claim 31
Dependent Claim
45 words
A method for producing a sustained zero-order time release of an active pharmaceutical agent in the gastro-intestinal tract utilizing an ingestible tablet prepared according to claim 23, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
Claim 32
Independent Claim
157 words
A method for facilitating the sustained time-release and absorption of large molecules of a pharmaceutically active agent through the mucosa of the buccal pouch of the mouth comprising: forming a buccal tablet containing a carrier of hydroxypropyl methylcellulose, hydroxypropyl cellulose and a carboxy vinyl polymer, together with an effective amount of a pharmaceutically active agent having a molecule size larger than the normal permeability of the mucosa in the buccal pouch of the mouth, and a sweetening agent at least thirty times as sweet as sugar; placing the buccal tablet in the buccal pouch of the mouth; and allowing saliva in the buccal pouch of the mouth to slowly dissolve the tablet such that the sweetener contacts the mucosa lining the buccal pouch of the mouth and causes an increase in the permeability of the mucosa to allow the molecules of the pharmaceutically active agent to penetrate and be absorbed into the bloodstream over a sustained period.
Claim 33
Independent Claim
157 words
A method for facilitating the sustained time-release and absorption of large molecules of a pharmaceutically active agent through the mucosa of the buccal pouch of the mouth comprising: forming a buccal tablet containing a carrier of hydroxypropyl methylcellulose, hydroxypropyl cellulose and a carboxy vinyl polymer, together with an effective amount of a pharmaceutically active agent having a molecule size larger than the normal permeability of the mucosa in the buccal pouch of the mouth, and a sweetening agent at least thirty times as sweet as sugar; placing the buccal tablet in the buccal pouch of the mouth; and allowing saliva in the buccal pouch of the mouth to slowly dissolve the tablet such that the sweetener contacts the mucosa lining the buccal pouch of the mouth and causes an increase in the permeability of the mucosa to allow the molecules of the pharmaceutically active agent to penetrate and be absorbed into the bloodstream over a sustained period.
Claim 34
Dependent Claim
54 words
A method for facilitating the sustained time-release and absorption of large molecules of a pharmaceutically active agent through the mucosa of the buccal pouch of the mouth, utilizing a buccal tablet prepared according to claim 25, wherein the carboxyvinyl polymer is a polymer of acrylic acid or polyacrylic acid, cross-linked with a polyalkenyl polyether.
References Cited (Backward Citations)
US2887440A
Cited
US3065143A
Cited
US3138524A
Cited
US3428728A
Cited
GB1171691A
Cited
US3590117A
Cited
GB1279214A
Cited
US3870790A
Cited
CA945899A
Cited
GB1430684A
Cited
US3876771A
Cited
GB1583801A
Cited
US4292299A
Cited
US4226849A
Cited
US4357469A
Cited
US4259314A
Cited
US4369172A
Cited
US4389393A
Cited
US4389393B1
Cited
US4572832A
Cited
US4540566A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-07-13 | 1991-01-12 | 1991-07-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-07-13 | 1995-01-12 | 1995-07-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-07-13 | 1999-01-12 | 1999-07-14 | $7700.00 | Window Closed / Lapsed |